MDxHealth

Historical price data

MDxHealth is a Nasdaq-listed precision diagnostics company dedicated to personalizing urologic care, primarily in prostate cancer. Its strategy centers on commercializing and expanding a menu of proprietary, non-invasive and tissue-based molecular tests, such as ConfirmMDx, GPS, SelectMDx, and ExoDx, which are supported by extensive clinical validation. The company aims to grow by increasing test adoption, securing favorable payer reimbursement, and leveraging its commercial infrastructure to enhance patient access and clinical utility.

A suite of molecular diagnostic technologies including epigenetic DNA methylation analysis, gene expression profiling (qRT-PCR), urinary mRNA/exosomal RNA detection, and antimicrobial susceptibility testing, tailored for urologic diseases.

MDxHealth faces direct competition in prostate cancer from Exact Sciences (Oncotype DX GPS), Veracyte (Decipher), and Myriad (Polaris), and in UTI testing from large reference labs and diagnostic majors. Its competitive edge lies in a focused urologic portfolio, strong clinical validation, and a strategy to own multiple decision points in the patient care pathway.